127 related articles for article (PubMed ID: 37748989)
1. Viability of focal dose escalation to prostate cancer intraprostatic lesions using HDR prostate brachytherapy.
Poder J; Radvan S; Howie A; Kasraei F; Parker A; Bucci J; Haworth A
Brachytherapy; 2023; 22(6):800-807. PubMed ID: 37748989
[TBL] [Abstract][Full Text] [Related]
2. Using multiparametric Magnetic Resonance Imaging and Prostate Specific Membrane Antigen Positron Emission Tomography to detect and delineate the gross tumour volume of intraprostatic lesions - A systematic review and meta-analysis.
Dhar A; Cendejas-Gomez JJ; Castro Mendez L; Boldt G; McArthur E; Zamboglou C; Bauman G
Radiother Oncol; 2024 Mar; 192():110070. PubMed ID: 38262815
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic efficiency of hybrid imaging using PSMA ligands, PET/CT, PET/MRI and MRI in identifying malignant prostate lesions.
Scobioala S; Kittel C; Wolters H; Huss S; Elsayad K; Seifert R; Stegger L; Weckesser M; Haverkamp U; Eich HT; Rahbar K
Ann Nucl Med; 2021 May; 35(5):628-638. PubMed ID: 33742373
[TBL] [Abstract][Full Text] [Related]
4. Clinical evaluation of an MRI-to-ultrasound deformable image registration algorithm for prostate brachytherapy.
Shaaer A; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
Brachytherapy; 2019; 18(1):95-102. PubMed ID: 30287271
[TBL] [Abstract][Full Text] [Related]
5. Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology.
Smith CW; Marcus T; Hoover D; Surry K; D'Souza D; Cool D; Kassam Z; Bastian-Jordan M; Gómez JA; Moussa M; Chin JL; Pautler S; Bauman GS; Ward AD
Brachytherapy; 2022; 21(4):435-441. PubMed ID: 35337747
[TBL] [Abstract][Full Text] [Related]
6. Comparison of [(11)C]choline Positron Emission Tomography With T2- and Diffusion-Weighted Magnetic Resonance Imaging for Delineating Malignant Intraprostatic Lesions.
Chang JH; Lim Joon D; Davis ID; Lee ST; Hiew CY; Esler S; Gong SJ; Wada M; Clouston D; O'Sullivan R; Goh YP; Bolton D; Scott AM; Khoo V
Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):438-45. PubMed ID: 25864171
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific membrane antigen positron emission tomography for lesion-directed high-dose-rate brachytherapy dose escalation.
Smith CW; Alfano R; Hoover D; Surry K; D'Souza D; Thiessen J; Rachinsky I; Butler J; Gomez JA; Gaed M; Moussa M; Chin J; Pautler S; Bauman GS; Ward AD
Phys Imaging Radiat Oncol; 2021 Jul; 19():102-107. PubMed ID: 34589619
[TBL] [Abstract][Full Text] [Related]
8. Comparison of
Zamboglou C; Drendel V; Jilg CA; Rischke HC; Beck TI; Schultze-Seemann W; Krauss T; Mix M; Schiller F; Wetterauer U; Werner M; Langer M; Bock M; Meyer PT; Grosu AL
Theranostics; 2017; 7(1):228-237. PubMed ID: 28042330
[TBL] [Abstract][Full Text] [Related]
9. A multiobserver study investigating the effectiveness of prostatic multiparametric magnetic resonance imaging to dose escalate corresponding histologic lesions using high-dose-rate brachytherapy.
Smith CW; Hoover D; Surry K; D'Souza D; Cool DW; Kassam Z; Bastian-Jordan M; Gomez JA; Moussa M; Chin J; Pautler S; Bauman GS; Ward AD
Brachytherapy; 2021; 20(3):601-610. PubMed ID: 33648893
[TBL] [Abstract][Full Text] [Related]
10. Focal dose escalation for prostate cancer using
Zamboglou C; Thomann B; Koubar K; Bronsert P; Krauss T; Rischke HC; Sachpazidis I; Drendel V; Salman N; Reichel K; Jilg CA; Werner M; Meyer PT; Bock M; Baltas D; Grosu AL
Radiat Oncol; 2018 May; 13(1):81. PubMed ID: 29716617
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer GTV delineation with biparametric MRI and
Hearn N; Blazak J; Vivian P; Vignarajah D; Cahill K; Atwell D; Lagopoulos J; Min M
Br J Radiol; 2021 Mar; 94(1119):20201174. PubMed ID: 33507812
[TBL] [Abstract][Full Text] [Related]
12. Dosimetric evaluation of MRI-to-ultrasound automated image registration algorithms for prostate brachytherapy.
Shaaer A; Paudel M; Davidson M; Semple M; Nicolae A; Mendez LC; Chung H; Loblaw A; Tseng CL; Morton G; Ravi A
Brachytherapy; 2020; 19(5):599-606. PubMed ID: 32712028
[TBL] [Abstract][Full Text] [Related]
13. Dose escalation to dominant intraprostatic lesions with MRI-transrectal ultrasound fusion High-Dose-Rate prostate brachytherapy. Prospective phase II trial.
Gomez-Iturriaga A; Casquero F; Urresola A; Ezquerro A; Lopez JI; Espinosa JM; Minguez P; Llarena R; Irasarri A; Bilbao P; Crook J
Radiother Oncol; 2016 Apr; 119(1):91-6. PubMed ID: 26900090
[TBL] [Abstract][Full Text] [Related]
14. [
Bettermann AS; Zamboglou C; Kiefer S; Jilg CA; Spohn S; Kranz-Rudolph J; Fassbender TF; Bronsert P; Nicolay NH; Gratzke C; Bock M; Ruf J; Benndorf M; Grosu AL
Radiother Oncol; 2019 Dec; 141():214-219. PubMed ID: 31431366
[TBL] [Abstract][Full Text] [Related]
15. The PRIMARY Score: Using Intraprostatic
Emmett L; Papa N; Buteau J; Ho B; Liu V; Roberts M; Thompson J; Moon D; Sheehan-Dare G; Alghazo O; Agrawal S; Murphy D; Stricker P; Hope TA; Hofman MS
J Nucl Med; 2022 Nov; 63(11):1644-1650. PubMed ID: 35301240
[TBL] [Abstract][Full Text] [Related]
16. Improved prostate delineation in prostate HDR brachytherapy with TRUS-CT deformable registration technology: A pilot study with MRI validation.
Yang X; Rossi PJ; Jani AB; Mao H; Zhou Z; Curran WJ; Liu T
J Appl Clin Med Phys; 2017 Jan; 18(1):202-210. PubMed ID: 28291925
[TBL] [Abstract][Full Text] [Related]
17. Synchronous vs independent reading of prostate-specific membrane antigen positron emission tomography (PSMA-PET) and magnetic resonance imaging (MRI) to improve diagnosis of prostate cancer.
Doan P; Counter W; Papa N; Sheehan-Dare G; Ho B; Lee J; Liu V; Thompson JE; Agrawal S; Roberts MJ; Buteau J; Hofman MS; Moon D; Lawrentschuk N; Murphy D; Stricker PD; Emmett L
BJU Int; 2023 May; 131(5):588-595. PubMed ID: 36371669
[TBL] [Abstract][Full Text] [Related]
18. MRI-TRUS registration methodology for TRUS-guided HDR prostate brachytherapy.
McGeachy P; Watt E; Husain S; Martell K; Martinez P; Sawhney S; Thind K
J Appl Clin Med Phys; 2021 Aug; 22(8):284-294. PubMed ID: 34318581
[TBL] [Abstract][Full Text] [Related]
19. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer.
Zamboglou C; Wieser G; Hennies S; Rempel I; Kirste S; Soschynski M; Rischke HC; Fechter T; Jilg CA; Langer M; Meyer PT; Bock M; Grosu AL
Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938
[TBL] [Abstract][Full Text] [Related]
20. Intraindividual comparison between
Spohn S; Jaegle C; Fassbender TF; Sprave T; Gkika E; Nicolay NH; Bock M; Ruf J; Benndorf M; Gratzke C; Grosu AL; Zamboglou C
Eur J Nucl Med Mol Imaging; 2020 Nov; 47(12):2796-2803. PubMed ID: 32342192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
